• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

    4.650 -0.010 (-0.21%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Tvardi Therapeutics, Inc. - Common Stock

    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
    From The Rosen Law Firm, P.A.
    Via Business Wire
    Unusual volume stocks in Monday's session
    In today's session, these stocks are experiencing unusual volume. 
    Via Chartmill
    In today's session, these stocks are experiencing unusual volume.
    Unusual volume stocks are being observed in Thursday's session. 
    Via Chartmill
    Unusual volume stocks in Wednesday's session
    Which stocks have an unusual volume on Wednesday? 
    Via Chartmill
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks
    Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response. 
    Via Benzinga
    Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge
     
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
     
    Via Benzinga
    Dow Surges 1%; Fastenal Shares Fall After Q3 Results
     
    Via Benzinga
    Topics Stocks
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?
    The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review... 
    Via Stocktwits
    Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Posts Q2 Net Income Turnaround
    Via The Motley Fool
    Topics Intellectual Property
    Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
    Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
    Via Benzinga
    This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
     
    Via Benzinga
    Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics to Participate in Upcoming Investor Conferences
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga
    Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.